Article
Eli Lilly bags an early-stage biotech for the neuro team — paying $135M cash and offering $1B-plu
Rating:
0.0
Views:
134
Likes:
1
Library:
1
Eli Lilly is snapping up a little Cambridge-based biotech to add to their neuro group. The pharma giant is getting Disarm Therapeutics and its SARM1 inhibitors for axonal degeneration, which has potential to be used for peripheral neuropathy, ALS and MS. It's costing Lilly $135 million cash plus up to
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value